Share on StockTwits

Shares of Smith & Nephew plc (NYSE:SNN) have earned an average recommendation of “Buy” from the fifteen ratings firms that are covering the company, AnalystRatings.NET reports. Seven analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $97.00.

Shares of Smith & Nephew plc (NYSE:SNN) traded up 0.02% on Monday, hitting $87.7799. 257,310 shares of the company’s stock traded hands. Smith & Nephew plc has a 52 week low of $57.99 and a 52 week high of $100.90. The stock has a 50-day moving average of $89.22 and a 200-day moving average of $79.09. The company has a market cap of $15.677 billion and a price-to-earnings ratio of 28.13.

Smith & Nephew plc (NYSE:SNN) last issued its quarterly earnings data on Thursday, May 1st. The company reported $0.89 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.93 by $0.04. On average, analysts predict that Smith & Nephew plc will post $4.13 earnings per share for the current fiscal year.

SNN has been the subject of a number of recent research reports. Analysts at Deutsche Bank reiterated a “buy” rating on shares of Smith & Nephew plc in a research note on Friday. Separately, analysts at Morgan Stanley reiterated an “overweight” rating on shares of Smith & Nephew plc in a research note on Thursday. Finally, analysts at Numis Securities Ltd reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Tuesday, July 8th.

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (NYSE:SNN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.